The Effect of Biofeedback-Based Virtual Reality Game on Children

Status Completed

Clinical Trial Summary

The needles of port catheters, which are often used in childhood cancer treatment, must be changed every 5-7 days, which causes pain, anxiety, and fear in children every 5-7 days In recent years, the usage of virtual reality has grown to distract children during port catheter needle insertion. But it's not always easy for children to switch their attention to something else. A good child distractor must be sensory-stimulating, developmentally appropriate, and highly interactive.

Clinical Trial Description

Today, virtual reality applications have advanced, and software that provides biofeedback with breathing has improved engagement with the user. Our aim in this study is to examine the effect of biofeedback-based virtual reality games on pair, fear and anxiety levels during insertion of port needle insertion in children. The randomized control trial design will be used, and The CONSORT list will be used to guide the research. This study will be conducted at the 62 pediatric oncology patients (31 experiment/ 31 control) aged 6-12 years. This study will be carry out in a university hospital in Istanbul, Turkey between January 2023, and June 2023. The research data will collect from the children's self-reports and parents through a survey form and scales. Children's pain will evaluate by the children and parent with Wong-Baker Faces Pain Rating Scale, child fear will evaluate by the children and parent with 'Child Fear Inventory', and child anxiety will evaluate by the children and parent with 'Child Anxiety Statement Scale'. ;

Study Design

Related Conditions & MeSH terms

Pediatric Cancer

Clinical Trial Details

NCT number	NCT05585840
Study type	Interventional
Source	Koç University
Contact
Status	Completed
Phase	N/A
Start date	July 15, 2023
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04262830` - Cancer Therapy Effects on the Heart
Not yet recruiting	`NCT06335745` - PediCARE Health Equity Intervention in High-Risk Neuroblastoma	N/A
Withdrawn	`NCT04719416` - Relaxation Therapy in Pediatric Oncology	N/A
Completed	`NCT01645436` - Physical Activity in Pediatric Cancer (PAPEC)	N/A
Completed	`NCT04409301` - Distress in the Pediatric Oncology Setting: Intervention Versus Natural Adaptation	N/A
Completed	`NCT04914702` - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting	`NCT05425043` - Granulocyte Transfusions After Umbilical Cord Blood Transplant	N/A
Recruiting	`NCT05071859` - Genetic Overlap Between Anomalies and Cancer in Kids in the Children's Oncology Group: The COG GOBACK Study
Recruiting	`NCT03241251` - Screening for Psychosocial Risk in Flemish Families of a Child With Cancer
Recruiting	`NCT05384288` - Response to Influenza Vaccination in Pediatric Oncology Patients
Completed	`NCT04586491` - The Effect of Oral Care Protocol on Prevention of Oral Mucositis in Pediatric Cancer Patients	N/A
Recruiting	`NCT05569512` - Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML	Phase 1/Phase 2
Enrolling by invitation	`NCT05294380` - Determination of Sarcopenia Risk and Related Factors in Pediatric Oncological Patients
Completed	`NCT02675166` - Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes
Completed	`NCT02665819` - Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility.	N/A
Not yet recruiting	`NCT05454163` - Post-radiotherapy Rhinosinusitis in Children
Terminated	`NCT02536183` - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors	Phase 1
Withdrawn	`NCT01828502` - Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer	Phase 2
Completed	`NCT02032121` - Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors	N/A
Completed	`NCT03964259` - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia	Phase 1